Akebia Therapeutics
AKBA
#9280
Rank
HK$1.24 B
Marketcap
HK$4.50
Share price
5.89%
Change (1 day)
-68.01%
Change (1 year)

Earnings for Akebia Therapeutics (AKBA)

Earnings in 2026 (TTM): -HK$0.34 Billion

According to Akebia Therapeutics's latest financial reports the company's current earnings are HK$0.19 Billion. In 2025 the company made an earning of -HK$29.19 Million, an increase over its 2024 earnings that were of -HK$0.55 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Akebia Therapeutics from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -HK$0.34 Billion1058.03%
2025 -HK$29.19 Million-94.64%
2024 -HK$0.55 Billion33.68%
2023 -HK$0.41 Billion-45.12%
2022 -HK$0.75 Billion-66.55%
2021 -HK$2.22 Billion-26.24%
2020 -HK$3.01 Billion33.94%
2019 -HK$2.25 Billion66.52%
2018 -HK$1.35 Billion123.53%
2017 -HK$0.61 Billion-43.34%
2016 -HK$1.07 Billion123.58%
2015 -HK$0.48 Billion63.95%
2014 -HK$0.3 Billion181.24%
2013 -HK$0.11 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
HK$146.83 B-43,455.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
HK$99.16 B-29,379.76%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Amgen
AMGN
HK$86.68 B-25,695.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Nektar Therapeutics
NKTR
-HK$1.21 Billion 254.59%๐Ÿ‡บ๐Ÿ‡ธ USA